JP2003513015A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003513015A5 JP2003513015A5 JP2001519702A JP2001519702A JP2003513015A5 JP 2003513015 A5 JP2003513015 A5 JP 2003513015A5 JP 2001519702 A JP2001519702 A JP 2001519702A JP 2001519702 A JP2001519702 A JP 2001519702A JP 2003513015 A5 JP2003513015 A5 JP 2003513015A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- aryl
- heterocycloalkyl
- alkynyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001072 heteroaryl group Chemical group 0.000 description 119
- 125000003118 aryl group Chemical group 0.000 description 117
- 125000000304 alkynyl group Chemical group 0.000 description 112
- 125000000753 cycloalkyl group Chemical group 0.000 description 112
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 112
- 125000003342 alkenyl group Chemical group 0.000 description 108
- 125000000547 substituted alkyl group Chemical group 0.000 description 104
- 0 C*(CC1)CCC1c(cc1)ccc1-c1nc2cccc3c2[n]1CCNC3=O Chemical compound C*(CC1)CCC1c(cc1)ccc1-c1nc2cccc3c2[n]1CCNC3=O 0.000 description 37
- 125000000217 alkyl group Chemical group 0.000 description 32
- 150000003839 salts Chemical class 0.000 description 31
- 229910052736 halogen Inorganic materials 0.000 description 24
- 150000002367 halogens Chemical class 0.000 description 24
- 239000002207 metabolite Substances 0.000 description 23
- 239000000651 prodrug Substances 0.000 description 23
- 229940002612 prodrug Drugs 0.000 description 23
- 239000012453 solvate Substances 0.000 description 23
- 229910052760 oxygen Inorganic materials 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 19
- 229910052717 sulfur Inorganic materials 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 17
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 14
- 125000004093 cyano group Chemical group *C#N 0.000 description 14
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 12
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 12
- 125000003277 amino group Chemical group 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 125000004104 aryloxy group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 125000005553 heteroaryloxy group Chemical group 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 125000005017 substituted alkenyl group Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- ROELIXRBIXJIOG-UHFFFAOYSA-N O=C1NCCC(C2)C(c(cc3)ccc3-c3ccncc3)=Nc3c2c1ccc3 Chemical compound O=C1NCCC(C2)C(c(cc3)ccc3-c3ccncc3)=Nc3c2c1ccc3 ROELIXRBIXJIOG-UHFFFAOYSA-N 0.000 description 2
- 239000012661 PARP inhibitor Substances 0.000 description 2
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 2
- 102100037664 Poly [ADP-ribose] polymerase tankyrase-1 Human genes 0.000 description 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 2
- 108010017601 Tankyrases Proteins 0.000 description 2
- -1 hydroxy, nitro, amino Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- BZXYEGGSSGOSIM-UHFFFAOYSA-N C=C(C1CC=C2)C=C(c3ccc[s]3)N(CCN3)C1=C2C3=O Chemical compound C=C(C1CC=C2)C=C(c3ccc[s]3)N(CCN3)C1=C2C3=O BZXYEGGSSGOSIM-UHFFFAOYSA-N 0.000 description 1
- GVTAOCLQEWVUAH-UHFFFAOYSA-N C=[F]c(cc1)ccc1C1=Cc2cccc3c2C1CCCCNC3=O Chemical compound C=[F]c(cc1)ccc1C1=Cc2cccc3c2C1CCCCNC3=O GVTAOCLQEWVUAH-UHFFFAOYSA-N 0.000 description 1
- SLSKEBAZNJLQAF-UHFFFAOYSA-N CC(/[O]=C(/CCC1)\CCC1c(cc1)ccc1-c1nc2cccc3c2[n]1CCNC3=O)=C Chemical compound CC(/[O]=C(/CCC1)\CCC1c(cc1)ccc1-c1nc2cccc3c2[n]1CCNC3=O)=C SLSKEBAZNJLQAF-UHFFFAOYSA-N 0.000 description 1
- ADSOSINJPNKUJK-UHFFFAOYSA-N CCCCc1ncccc1 Chemical compound CCCCc1ncccc1 ADSOSINJPNKUJK-UHFFFAOYSA-N 0.000 description 1
- XDCGESSCGGOREE-UHFFFAOYSA-N CN(CCCC1)C1c(cc1)ccc1C1=Nc2cccc3c2CCC1CCNC3=O Chemical compound CN(CCCC1)C1c(cc1)ccc1C1=Nc2cccc3c2CCC1CCNC3=O XDCGESSCGGOREE-UHFFFAOYSA-N 0.000 description 1
- FSBYWAPDIVFGHZ-INIZCTEOSA-N Cc(cc1)ccc1C1=Cc2cccc3c2[C@H]1CCCNC3=O Chemical compound Cc(cc1)ccc1C1=Cc2cccc3c2[C@H]1CCCNC3=O FSBYWAPDIVFGHZ-INIZCTEOSA-N 0.000 description 1
- XYJIKZQLRLLMNR-UHFFFAOYSA-N NCc(cc1)ccc1-c(c(CCNC1=O)c2)nc3c2c1cc(F)c3 Chemical compound NCc(cc1)ccc1-c(c(CCNC1=O)c2)nc3c2c1cc(F)c3 XYJIKZQLRLLMNR-UHFFFAOYSA-N 0.000 description 1
- GXNDKAHDTWOGOA-UHFFFAOYSA-N O=C(c1ccc2)NCCc3cc1c2nc3-c1ccc(C2NCCCC2)cc1 Chemical compound O=C(c1ccc2)NCCc3cc1c2nc3-c1ccc(C2NCCCC2)cc1 GXNDKAHDTWOGOA-UHFFFAOYSA-N 0.000 description 1
- MZHKZUQKRRERNT-UHFFFAOYSA-N O=C1NCCC2C(c(cc3)ccc3F)=Nc3c2c1ccc3 Chemical compound O=C1NCCC2C(c(cc3)ccc3F)=Nc3c2c1ccc3 MZHKZUQKRRERNT-UHFFFAOYSA-N 0.000 description 1
- WTRLEQBHPVZRBL-HNNXBMFYSA-N O=C1NCCC[C@@H]2c3c1cccc3C=C2c(cc1)ccc1F Chemical compound O=C1NCCC[C@@H]2c3c1cccc3C=C2c(cc1)ccc1F WTRLEQBHPVZRBL-HNNXBMFYSA-N 0.000 description 1
- FXVARHWMURCUDT-UHFFFAOYSA-N O=C1NCCN2C(c3cccc(CN4CCCC4)c3)=NC3=CC=CC1C23 Chemical compound O=C1NCCN2C(c3cccc(CN4CCCC4)c3)=NC3=CC=CC1C23 FXVARHWMURCUDT-UHFFFAOYSA-N 0.000 description 1
- ZHFXLZSZUBSOBW-UHFFFAOYSA-N O=C1NCC[n]2c(-c(cc3)ccc3F)nc3cc(F)cc1c23 Chemical compound O=C1NCC[n]2c(-c(cc3)ccc3F)nc3cc(F)cc1c23 ZHFXLZSZUBSOBW-UHFFFAOYSA-N 0.000 description 1
- XLFLIGQYRJBFHN-UHFFFAOYSA-N O=C1NCC[n]2c(-c(cc3)ccc3F)nc3cccc1c23 Chemical compound O=C1NCC[n]2c(-c(cc3)ccc3F)nc3cccc1c23 XLFLIGQYRJBFHN-UHFFFAOYSA-N 0.000 description 1
- QVDJUNLKWJHUPW-UHFFFAOYSA-N O=C1NCC[n]2c(-c3ccc(C4NCCCC4)cc3)nc3c2c1ccc3 Chemical compound O=C1NCC[n]2c(-c3ccc(C4NCCCC4)cc3)nc3c2c1ccc3 QVDJUNLKWJHUPW-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15214299P | 1999-08-31 | 1999-08-31 | |
| US60/152,142 | 1999-08-31 | ||
| PCT/US2000/023882 WO2001016136A2 (en) | 1999-08-31 | 2000-08-31 | Tricyclic inhibitors of poly(adp-ribose) polymerases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003513015A JP2003513015A (ja) | 2003-04-08 |
| JP2003513015A5 true JP2003513015A5 (enExample) | 2006-09-21 |
| JP4272375B2 JP4272375B2 (ja) | 2009-06-03 |
Family
ID=22541675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001519702A Expired - Lifetime JP4272375B2 (ja) | 1999-08-31 | 2000-08-31 | ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤 |
Country Status (48)
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| PL347885A1 (en) * | 1999-09-28 | 2002-04-22 | Basf Ag | Azepinoindole derivatives, the production and use thereof |
| DE19946289A1 (de) * | 1999-09-28 | 2001-03-29 | Basf Ag | Benzodiazepin-Derivate, deren Herstellung und Anwendung |
| DE10021468A1 (de) * | 2000-05-04 | 2001-11-08 | Basf Ag | Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen |
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| FR2816942B1 (fr) * | 2000-11-23 | 2003-05-09 | Sanofi Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
| WO2003051879A1 (en) * | 2001-12-14 | 2003-06-26 | Altana Pharma Ag | Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors |
| US7026311B2 (en) | 2002-01-10 | 2006-04-11 | Abbott Gmbh & Co., Kg | Dibenzodiazepine derivatives, their preparation and use |
| JP4500161B2 (ja) | 2002-04-30 | 2010-07-14 | クドス ファーマシューティカルズ リミテッド | フタラジノン誘導体 |
| WO2003103666A2 (en) * | 2002-06-07 | 2003-12-18 | Altana Pharma Ag | Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones |
| EP1947102A1 (en) | 2003-01-09 | 2008-07-23 | Pfizer, Inc. | Compositions comprising diazepinoindole derivatives as kinase inhibitors |
| GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| BRPI0412899B1 (pt) * | 2003-07-25 | 2021-10-05 | Cancer Research Technology Limited | Uso de um composto ou um sal farmaceuticamente aceitável do mesmo para a manufatura de um medicamento citotóxico para o tratamento de câncer de ovário, câncer de mama, câncer de próstata ou câncer pancreático |
| GB0317466D0 (en) * | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| WO2005035534A1 (ja) * | 2003-10-08 | 2005-04-21 | Ono Pharmaceutical Co., Ltd. | 複素ビシクロ環および複素トリシクロ環化合物およびその医薬 |
| EP1684736B1 (en) | 2003-12-01 | 2011-08-24 | Kudos Pharmaceuticals Limited | Dna damage repair inhibitors for treatment of cancer |
| GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| KR100876520B1 (ko) * | 2004-09-22 | 2008-12-31 | 화이자 인코포레이티드 | 폴리(ａｄｐ-리보오스) 폴리머라제 억제제의 제조 방법 |
| CN101223175B (zh) * | 2005-01-19 | 2013-03-27 | 卫材有限公司 | 二氮杂苯并[de]蒽-3-酮化合物及抑制PARP的方法 |
| CA2609562A1 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Macrocyclic heterocyclic aspartyl protease inhibitors |
| WO2006137510A1 (ja) * | 2005-06-24 | 2006-12-28 | Ono Pharmaceutical Co., Ltd. | 脳血管障害時における出血低減剤 |
| CN102335163A (zh) * | 2005-07-18 | 2012-02-01 | 彼帕科学公司 | 癌症的治疗 |
| JP2009503069A (ja) * | 2005-08-05 | 2009-01-29 | アストラゼネカ アクチボラグ | 三環式ベンゾイミダゾール類、および代謝性グルタミン酸塩受容体のモジュレータとしてのそれらの使用 |
| GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| EP2038654A4 (en) * | 2006-06-12 | 2010-08-11 | Bipar Sciences Inc | METHOD FOR THE TREATMENT OF DISEASES WITH PARP INHIBITORS |
| US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| US20080262062A1 (en) * | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| WO2008030883A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
| JP2010502731A (ja) * | 2006-09-05 | 2010-01-28 | バイパー サイエンシズ，インコーポレイティド | Ｐａｒｐ阻害剤による脂肪酸合成の阻害、及びその治療方法 |
| UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
| KR20100038295A (ko) | 2007-06-05 | 2010-04-14 | 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 | 피질 카테콜아민성 신경 전달의 조정자로서의 이치환된 페닐피롤리딘 |
| WO2008154129A1 (en) * | 2007-06-08 | 2008-12-18 | Bausch & Lomb Incorporated | Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye |
| EP2188278A1 (en) | 2007-09-14 | 2010-05-26 | AstraZeneca AB | Phthalazinone derivatives |
| AU2008321128A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| SG185954A1 (en) * | 2007-11-12 | 2012-12-28 | Bipar Sciences Inc | Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
| US20090149397A1 (en) * | 2007-12-07 | 2009-06-11 | Bipar Sciences | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
| AR070221A1 (es) | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
| JP2011521618A (ja) * | 2008-02-04 | 2011-07-28 | バイパー サイエンシズ，インコーポレイティド | Ｐａｒｐ仲介疾患を診断および治療する方法 |
| GB0804755D0 (en) | 2008-03-14 | 2008-04-16 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| MX2011003740A (es) | 2008-10-07 | 2011-05-02 | Astrazeneca Uk Ltd | Formulacion farmaceutica - 514. |
| WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| US20150218110A1 (en) * | 2012-09-05 | 2015-08-06 | Bayer Cropscience Ag | Use of substituted benzodiazepinones and benzazepinones or the salts thereof as active substances against abiotic plant stress |
| ES2700348T3 (es) * | 2014-01-05 | 2019-02-15 | Univ Washington | Trazadores radioetiquetados para poli (ADP-ribosa) polimerasa-1 (PARP-1), métodos y usos para estos |
| EP3325623B3 (en) | 2015-07-23 | 2021-01-20 | Institut Curie | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| WO2018022851A1 (en) | 2016-07-28 | 2018-02-01 | Mitobridge, Inc. | Methods of treating acute kidney injury |
| SG11201903842YA (en) | 2016-11-02 | 2019-05-30 | Immunogen Inc | Combination treatment with antibody-drug conjugates and parp inhibitors |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| EP3615026B1 (en) | 2017-04-28 | 2021-03-03 | Akribes Biomedical GmbH | A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing |
| KR20200121800A (ko) | 2018-01-05 | 2020-10-26 | 싸이브렉사 1, 인크. | 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법 |
| KR20200130856A (ko) | 2018-03-13 | 2020-11-20 | 옹쎄오 | 암 치료에서 획득한 내성에 대한 디베이트 분자 |
| US11535633B2 (en) | 2018-06-28 | 2022-12-27 | Jiangsu Hengrui Medicine Co., Ltd. | Fused tricyclic heterocycle compounds and therapeutic uses thereof |
| CN112552314B (zh) * | 2018-08-24 | 2022-03-04 | 杭州阿诺生物医药科技有限公司 | Sting激动剂小分子抗肿瘤化合物及其应用 |
| WO2020124059A1 (en) * | 2018-12-14 | 2020-06-18 | Eternity Bioscience Inc. | Tricyclic compounds as sting agonists, and preparation methods and medicinal uses thereof |
| CN116804019A (zh) * | 2019-02-02 | 2023-09-26 | 正大天晴药业集团股份有限公司 | 用于parp抑制剂的吲哚并七元酰肟类似物 |
| CN111909157B (zh) * | 2019-05-07 | 2023-02-03 | 南京药石科技股份有限公司 | Ezh2抑制剂及其用途 |
| CN114341162B (zh) | 2019-07-10 | 2025-10-17 | 赛博克萨2公司 | 作为治疗剂的细胞毒素的肽缀合物 |
| US11555019B2 (en) | 2019-07-10 | 2023-01-17 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
| GB201913030D0 (en) | 2019-09-10 | 2019-10-23 | Francis Crick Institute Ltd | Treatment of hr deficient cancer |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US20230234938A1 (en) | 2020-04-28 | 2023-07-27 | Rhizen Pharmaceuticals Ag | Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors |
| WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| EP4274905A1 (en) | 2021-01-08 | 2023-11-15 | Cybrexa 2, Inc. | Process for preparing a conjugate linking moiety |
| WO2022155172A1 (en) | 2021-01-13 | 2022-07-21 | Cybrexa 3, Inc. | Peptide conjugates of therapeutics |
| IL307339A (en) | 2021-04-08 | 2023-11-01 | Rhizen Pharmaceuticals Ag | Poly(ADP-ribose) polymerase inhibitors |
| WO2024261243A1 (en) | 2023-06-21 | 2024-12-26 | Hemispherian As | Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer |
| WO2025106920A1 (en) * | 2023-11-15 | 2025-05-22 | Yale University | Parp pet imaging agents and methods of using the same |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997004771A1 (en) * | 1995-08-02 | 1997-02-13 | Newcastle University Ventures Limited | Benzimidazole compounds |
| GB1052390A (enExample) | 1964-03-24 | |||
| US3642820A (en) * | 1969-11-03 | 1972-02-15 | Upjohn Co | 4 5-dihydropyrrolo(3 2 1-jk)(1 4)bezodiazepines |
| US3734919A (en) * | 1969-11-03 | 1973-05-22 | Upjohn Co | 4,5-di-hydropyrrolo(3,2,1-jk)(1,4)benzodiazepin-7(6h)-ones and 4,5-di-hydropyrrolo(1,2,3-ef)(1,5)benzodiazepin-6(7h)-ones |
| DE2056215A1 (de) | 1970-11-16 | 1972-05-18 | Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt | Verfahren zur Herstellung von N-Mono-(beta-Cyanäthyl>anilinen |
| US3883590A (en) | 1971-06-01 | 1975-05-13 | Universal Oil Prod Co | Preparation of n-alkylarylcarboxamides |
| US3950343A (en) | 1973-11-06 | 1976-04-13 | Ayerst, Mckenna And Harrison Ltd. | Pyrroloisoquinoline derivatives |
| US3978066A (en) | 1973-11-06 | 1976-08-31 | Ayerst, Mckenna And Harrison Ltd. | Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives |
| US3900477A (en) | 1973-11-06 | 1975-08-19 | Ayerst Mckenna & Harrison | 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives |
| JPS57144286A (en) | 1981-03-02 | 1982-09-06 | Takeda Chem Ind Ltd | Azepinoindole derivative and its preparation |
| US4910193A (en) | 1985-12-16 | 1990-03-20 | Sandoz Ltd. | Treatment of gastrointestinal disorders |
| DE4125292A1 (de) | 1991-07-31 | 1993-02-04 | Kali Chemie Pharma Gmbh | 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US5342946A (en) | 1992-12-02 | 1994-08-30 | Guilford Pharmaceuticals Inc. | Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors |
| AU674613B2 (en) | 1993-09-28 | 1997-01-02 | Otsuka Pharmaceutical Co., Ltd. | Quinoxaline derivative as antidiabetic agent |
| US5587384A (en) | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
| GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| US5561161A (en) | 1994-03-25 | 1996-10-01 | Oxigene, Inc. | Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof |
| US5589483A (en) | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
| ES2105959B1 (es) | 1995-01-17 | 1998-07-01 | Zeneca Pharma Sa | Derivados de 1,4-dioxido de quinoxalina, procedimiento de preparacion y de utilizacion. |
| US5756548A (en) | 1995-04-03 | 1998-05-26 | Centaur Pharmaceuticals, Inc. | Acetamidobenzamide compounds for neurodegenerative disorders |
| US5659082A (en) | 1995-04-03 | 1997-08-19 | Centaur Pharmaceuticals, Inc. | Nitro- and aminobenzamide compounds for neurodegenerative disorders |
| HUT76302A (en) | 1995-11-30 | 1997-07-28 | Chinoin Gyogyszer Es Vegyeszet | Quinoxaline derivatives, pharmaceutical compositions containing them and process for producing them |
| GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
| CN1198614C (zh) | 1997-05-13 | 2005-04-27 | 奥科特默股份有限公司 | pADPRT抑制剂在用于制备治疗炎症和炎性疾病的药物中的方法 |
| AU9298198A (en) | 1997-09-03 | 1999-03-22 | Guilford Pharmaceuticals Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
| US20020028813A1 (en) | 1997-09-03 | 2002-03-07 | Paul F. Jackson | Thioalkyl compounds, methods, and compositions for inhibiting parp activity |
| US20020022636A1 (en) | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| US6197785B1 (en) | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
| US6635642B1 (en) | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| WO1999011622A1 (en) | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Amino-substituted compounds, methods, and compositions for inhibiting parp activity |
| CA2332239A1 (en) | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
| EP1077944A1 (en) | 1998-05-15 | 2001-02-28 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, compositions, and methods for inhibiting parp activity |
-
2000
- 2000-08-29 EC EC2000003637A patent/ECSP003637A/es unknown
- 2000-08-30 MY MYPI20004039A patent/MY135910A/en unknown
- 2000-08-30 CO CO00065062A patent/CO5200769A1/es not_active Application Discontinuation
- 2000-08-30 GT GT200000145A patent/GT200000145A/es unknown
- 2000-08-31 OA OA1200200064A patent/OA12016A/en unknown
- 2000-08-31 US US09/653,184 patent/US6548494B1/en not_active Expired - Lifetime
- 2000-08-31 EP EP00961437A patent/EP1208104B1/en not_active Expired - Lifetime
- 2000-08-31 CA CA002382404A patent/CA2382404C/en not_active Expired - Fee Related
- 2000-08-31 SV SV2000000162A patent/SV2003000162A/es unknown
- 2000-08-31 NZ NZ516793A patent/NZ516793A/en unknown
- 2000-08-31 SI SI200030643T patent/SI1208104T1/xx unknown
- 2000-08-31 PT PT00961437T patent/PT1208104E/pt unknown
- 2000-08-31 MX MXPA02002138A patent/MXPA02002138A/es active IP Right Grant
- 2000-08-31 EE EEP200200100A patent/EE200200100A/xx unknown
- 2000-08-31 AT AT00961437T patent/ATE287406T1/de not_active IP Right Cessation
- 2000-08-31 AU AU73389/00A patent/AU781826B2/en not_active Ceased
- 2000-08-31 PA PA20008501801A patent/PA8501801A1/es unknown
- 2000-08-31 DE DE60017575T patent/DE60017575T2/de not_active Expired - Lifetime
- 2000-08-31 JP JP2001519702A patent/JP4272375B2/ja not_active Expired - Lifetime
- 2000-08-31 HK HK02106977.2A patent/HK1045509B/en not_active IP Right Cessation
- 2000-08-31 AP APAP/P/2002/002449A patent/AP1553A/en active
- 2000-08-31 PL PL00354242A patent/PL354242A1/xx not_active Application Discontinuation
- 2000-08-31 ES ES00961437T patent/ES2234657T3/es not_active Expired - Lifetime
- 2000-08-31 BR BR0015051-7A patent/BR0015051A/pt not_active Application Discontinuation
- 2000-08-31 HR HR20020271A patent/HRP20020271A2/hr not_active Application Discontinuation
- 2000-08-31 KR KR1020027002629A patent/KR20020038742A/ko not_active Abandoned
- 2000-08-31 CZ CZ2002613A patent/CZ2002613A3/cs unknown
- 2000-08-31 GE GEAP20006389A patent/GEP20043268B/en unknown
- 2000-08-31 CN CN00815066A patent/CN1384835A/zh active Pending
- 2000-08-31 YU YU15102A patent/YU15102A/sh unknown
- 2000-08-31 AR ARP000104549A patent/AR035162A1/es unknown
- 2000-08-31 WO PCT/US2000/023882 patent/WO2001016136A2/en not_active Ceased
- 2000-08-31 DK DK00961437T patent/DK1208104T3/da active
- 2000-08-31 HU HU0202703A patent/HUP0202703A3/hu unknown
- 2000-08-31 UY UY26323A patent/UY26323A1/es not_active Application Discontinuation
- 2000-08-31 SK SK259-2002A patent/SK2592002A3/sk unknown
- 2000-08-31 PE PE2000000896A patent/PE20010538A1/es not_active Application Discontinuation
- 2000-08-31 DZ DZ003216A patent/DZ3216A1/fr active
- 2000-08-31 UA UA2002042574A patent/UA73144C2/uk unknown
- 2000-08-31 EA EA200200306A patent/EA200200306A1/ru unknown
- 2000-08-31 IL IL14786300A patent/IL147863A0/xx unknown
- 2000-09-20 DO DO2000000069A patent/DOP2000000069A/es unknown
-
2002
- 2002-01-28 NO NO20020421A patent/NO322475B1/no unknown
- 2002-01-30 ZA ZA200200830A patent/ZA200200830B/en unknown
- 2002-02-01 CR CR6577A patent/CR6577A/es not_active Application Discontinuation
- 2002-02-27 IS IS6289A patent/IS6289A/is unknown
- 2002-03-29 MA MA26577A patent/MA25876A1/fr unknown
- 2002-03-29 BG BG106562A patent/BG106562A/bg unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003513015A5 (enExample) | ||
| JP2002534523A5 (enExample) | ||
| CA2360003A1 (en) | Tricyclic inhibitors of poly(adp-ribose) polymerases | |
| WO2004074270A3 (en) | Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same | |
| AR063351A1 (es) | DERIVADOS DE PURINA Y DE PIRIMIDINAS CONDENSADAS, COMPOSICION Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA INHIBIR EL HSP90 EN UNA CELULA. | |
| JP2009536660A5 (enExample) | ||
| WO2000057861A3 (en) | Use of cytidine derivatives for the treatment of leukaemia | |
| RU2469042C2 (ru) | Терапевтически активные триазолы и их использование | |
| JP2006505543A5 (enExample) | ||
| JP2012519691A5 (enExample) | ||
| JP2007535491A5 (enExample) | ||
| JP2007515405A5 (enExample) | ||
| JP2007534636A5 (enExample) | ||
| JP2009504764A5 (enExample) | ||
| RU2007116119A (ru) | Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с | |
| JP2008504233A5 (enExample) | ||
| JP2005531488A5 (enExample) | ||
| JP2013523765A5 (enExample) | ||
| JP2002502874A5 (enExample) | ||
| JP2002539128A5 (enExample) | ||
| RU2012117829A (ru) | Фосфорамидатные производные нуклеозидов | |
| AR040661A1 (es) | Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2 | |
| AR037488A1 (es) | El uso de un compuesto derivado de imidazo (1,2-a) piridina, un compuesto derivado de imidazo (1,2-a) piridina, y un medicamento que contiene dicho compuesto. | |
| WO2007138110A3 (en) | Compounds that interact with ion channels, in particular with ion channels from the kv family | |
| RU2008135332A (ru) | Ингибиторы киназ и способы их применения |